Swedencare AB (publ) (SECARE.ST)

SEK 35.25

(-0.7%)

EBITDA Summary of Swedencare AB (publ)

Swedencare AB (publ)'s latest annual EBITDA in 2023 was 484 Million SEK , up 20.93% from previous year.
Swedencare AB (publ)'s latest quarterly EBITDA in 2024 Q3 was 133.9 Million SEK , down -4.56% from previous quarter.
Swedencare AB (publ) reported an annual EBITDA of 392.39 Million SEK in 2022, up 185.18% from previous year.
Swedencare AB (publ) reported an annual EBITDA of 138.73 Million SEK in 2021, up 111.04% from previous year.
Swedencare AB (publ) reported a quarterly EBITDA of 134.5 Million SEK for 2024 Q1, up 0.89% from previous quarter.
Swedencare AB (publ) reported a quarterly EBITDA of 133.9 Million SEK for 2024 Q3, down -4.56% from previous quarter.

Annual EBITDA Chart of Swedencare AB (publ) (2023 - 2013)

Historical Annual EBITDA of Swedencare AB (publ) (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	484 Million SEK	20.93%
2022	392.39 Million SEK	185.18%
2021	138.73 Million SEK	111.04%
2020	54.87 Million SEK	62.73%
2019	40.07 Million SEK	31.16%
2018	30.55 Million SEK	34.13%
2017	22.77 Million SEK	57.08%
2016	14.13 Million SEK	4.79%
2015	8.72 Million SEK	200.13%
2014	6.2 Million SEK	408.05%
2013	-1.49 Million SEK	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	139.1 Million SEK	2.86%
2024 Q1	134.5 Million SEK	0.89%
2024 Q3	133.9 Million SEK	-4.56%
2023 Q1	105.1 Million SEK	-6.63%
2023 FY	- SEK	20.93%
2023 Q2	107.9 Million SEK	2.66%
2023 Q3	136.1 Million SEK	26.14%
2023 Q4	133.4 Million SEK	-1.98%
2022 Q1	57.72 Million SEK	1673.49%
2022 FY	- SEK	185.18%
2022 Q3	88.28 Million SEK	-19.8%
2022 Q4	112.55 Million SEK	27.49%
2022 Q2	110.08 Million SEK	90.69%
2021 Q2	46.73 Million SEK	26.02%
2021 Q3	50.41 Million SEK	7.87%
2021 Q4	3.25 Million SEK	-93.54%
2021 Q1	37.08 Million SEK	36.68%
2021 FY	- SEK	111.04%
2020 Q3	20 Million SEK	207.6%
2020 Q2	6.5 Million SEK	-43.73%
2020 FY	- SEK	62.73%
2020 Q4	27.13 Million SEK	35.64%
2020 Q1	11.55 Million SEK	53.96%
2019 Q3	11.78 Million SEK	25.61%
2019 Q2	9.38 Million SEK	-17.6%
2019 Q1	11.38 Million SEK	49.39%
2019 FY	- SEK	31.16%
2019 Q4	7.5 Million SEK	-36.31%
2018 Q1	6.28 Million SEK	-9.89%
2018 Q3	8.86 Million SEK	15.27%
2018 Q4	7.62 Million SEK	-14.0%
2018 FY	- SEK	34.13%
2018 Q2	7.69 Million SEK	22.3%
2017 Q3	5.73 Million SEK	101.97%
2017 Q4	6.97 Million SEK	21.65%
2017 FY	- SEK	57.08%
2017 Q1	7.13 Million SEK	210.14%
2017 Q2	2.84 Million SEK	-60.19%
2016 Q1	4.75 Million SEK	-1.53%
2016 Q4	2.3 Million SEK	-51.33%
2016 Q3	4.72 Million SEK	73.49%
2016 Q2	2.72 Million SEK	-42.7%
2016 FY	- SEK	4.79%
2015 Q1	2.32 Million SEK	0.0%
2015 FY	- SEK	200.13%
2015 Q4	4.82 Million SEK	58.3%
2015 Q2	3.64 Million SEK	56.6%
2015 Q3	3.05 Million SEK	-16.23%
2014 FY	- SEK	408.05%
2013 FY	- SEK	0.0%

Peer EBITDA Comparison of Swedencare AB (publ)

Name	EBITDA	EBITDA Difference
AcuCort AB	-13.69 Million SEK	3635.169%
AlzeCure Pharma AB (publ)	-37.86 Million SEK	1378.124%
BioGaia AB (publ)	466.19 Million SEK	-3.82%
Enzymatica AB (publ)	-41.12 Million SEK	1276.986%
Enorama Pharma AB (publ)	-43.05 Million SEK	1224.196%
Gabather AB (publ)	37 Thousand SEK	-1308008.108%
Klaria Pharma Holding AB (publ.)	-14.77 Million SEK	3376.913%
Moberg Pharma AB (publ)	-26.95 Million SEK	1895.297%
Nanexa AB (publ)	-70.79 Million SEK	783.703%
Newbury Pharmaceuticals AB (publ)	-12.34 Million SEK	4022.204%
ODI Pharma AB	1.36 Million SEK	-35296.599%
Orexo AB (publ)	-22 Million SEK	2300.0%
Probi AB (publ)	115.61 Million SEK	-318.642%
Swedish Orphan Biovitrum AB (publ)	7.23 Billion SEK	93.309%
Toleranzia AB	-7.39 Million SEK	6642.309%
Vivesto AB	-89.75 Million SEK	639.228%